Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00707889 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

A Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
159
Enrollment target
20
Study locations

NCT00707889: Completed Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer, sponsored by AbbVie (prior sponsor, Abbott).

NCT00707889 is a Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 159 participants, below the 897-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00707889, a Phase 2 study of Adenocarcinoma of the Rectum and Advanced Colorectal Cancer, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
159 participants
Enrollment target
20
Study locations

Study Summary

To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.

Conditions Studied

Adenocarcinoma of the Rectum Advanced Colorectal Cancer Adenocarcinoma of the Colon

Interventions

  • DRUG bevacizumab
  • DRUG oxaliplatin
  • DRUG fluorouracil
  • DRUG folinic acid
  • DRUG ABT-869

Study Locations (20)

Other

  • Site Reference ID/Investigator# 18581 - Bedford Park
  • Site Reference ID/Investigator# 23443 - Herston
  • Site Reference ID/Investigator# 18023 - Bonheiden
  • Site Reference ID/Investigator# 23646 - Brussels
  • Site Reference ID/Investigator# 18026 - Leuven
  • Site Reference ID/Investigator# 18022 - Roeselare
  • Site Reference ID/Investigator# 26662 - Jaú
  • Site Reference ID/Investigator# 24245 - Porto Alegre
  • Site Reference ID/Investigator# 23265 - Barrie
  • Site Reference ID/Investigator# 21083 - Edmonton
  • Site Reference ID/Investigator# 22465 - Ottawa
  • Site Reference ID/Investigator# 22141 - Náchod
  • Site Reference ID/Investigator# 22289 - Heraklion
  • Site Reference ID/Investigator# 22286 - Thessaloniki
  • Site Reference ID/Investigator# 22287 - Thessaloniki
  • Site Reference ID/Investigator# 20281 - Wellington South
  • Site Reference ID/Investigator# 20141 - Olsztyn

North Carolina

  • Site Reference ID/Investigator# 11341 - Chapel Hill

Pennsylvania

  • Site Reference ID/Investigator# 20801 - Philadelphia

Tennessee

  • Site Reference ID/Investigator# 8360 - Nashville

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2008-10
Est. Completion 2012-05
Phase Phase 2
AbbVie (prior sponsor, Abbott)

88 total trials

What the finished NCT00707889 record still lists

NCT00707889 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 897-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 5 interventions - of which bevacizumab is the first listed.

NCT00707889 names 20 study sites across 4 states, led by Other, North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00707889 about?

NCT00707889 is a clinical study titled "Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer". To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.

What is the current status of trial NCT00707889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2008-10. Estimated completion is 2012-05.

What conditions does trial NCT00707889 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Advanced Colorectal Cancer, Adenocarcinoma of the Colon.

What interventions are being tested in trial NCT00707889?

The interventions under investigation include: bevacizumab (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), folinic acid (DRUG), ABT-869 (DRUG).

Who is sponsoring clinical trial NCT00707889?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00707889 being conducted?

This trial has 20 study locations across North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenocarcinoma of the Rectum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00707889's enrollment target sits among peer trials

159 2nd of 11 the highest of 11 other Adenocarcinoma of the Rectum trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adenocarcinoma of the Rectum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05267626 · 159 participants · Phase 1

    Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • NCT06321575 · 159 participants · NA

    The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

  • NCT06729151 · 159 participants

    Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome

  • NCT07023731 · 159 participants · Phase 1

    A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00707889, the US trial registry maintained by the National Library of Medicine. NCT00707889 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.